View Item 

Show simple item record

Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?
dc.contributor.authorZoulim, Fabienen_US
dc.contributor.authorButi, M.en_US
dc.contributor.authorLok, Anna Suk-Fongen_US
dc.date.accessioned2010-06-01T18:39:58Z
dc.date.available2010-06-01T18:39:58Z
dc.date.issued2007-11en_US
dc.identifier.citationZoulim, F.; Buti, M.; Lok, A. S. (2007). "Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?." Journal of Viral Hepatitis 14(s1): 29-36. <http://hdl.handle.net/2027.42/71866>en_US
dc.identifier.issn1352-0504en_US
dc.identifier.issn1365-2893en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71866
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17958640&dopt=citationen_US
dc.format.extent273093 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 The Authors Journal compilation 2007 Blackwell Publishing Ltden_US
dc.subject.otherAntiviral Drugsen_US
dc.subject.otherAntiviral Therapyen_US
dc.subject.otherChronic Hepatitisen_US
dc.subject.otherDrug Resistanceen_US
dc.subject.otherHepatitis B Virusen_US
dc.subject.otherViral Genome Variabilityen_US
dc.titleAntiviral-resistant hepatitis B virus: can we prevent this monster from growing?en_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherINSERM, U871, 69003 Lyon, Franceen_US
dc.contributor.affiliationotherUniversitÉ Lyon 1, IFR62 Lyon-Est, 69008 Lyon, Franceen_US
dc.contributor.affiliationotherHospices Civils de Lyon, HÔtel Dieu, Department of Liver Diseases, 69002 Lyon, Franceen_US
dc.contributor.affiliationotherHospital General Universitario Valle de Hebron, Barcelona, Spainen_US
dc.identifier.pmid17958640en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71866/1/j.1365-2893.2007.00915.x.pdf
dc.identifier.doi10.1111/j.1365-2893.2007.00915.xen_US
dc.identifier.sourceJournal of Viral Hepatitisen_US
dc.identifier.citedreferenceZoulim F.. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 1 – 15.en_US
dc.identifier.citedreferenceDelmas J, Schorr O, Jamard C et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002; 46: 425 – 433.en_US
dc.identifier.citedreferenceWerle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750 – 1758.en_US
dc.identifier.citedreferenceGunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52: 25 – 137.en_US
dc.identifier.citedreferenceColonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naÏve patients with hepatitis B. Hepatology 2006; 44: 1656 – 1665.en_US
dc.identifier.citedreferenceFung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283 – 290.en_US
dc.identifier.citedreferenceLai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687 – 696.en_US
dc.identifier.citedreferenceBenhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302 – 1306.en_US
dc.identifier.citedreferenceLitwin S, Toll E, Jilbert AR, Mason WS. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol 2005; 34 ( Suppl. 1 ): S96 – S107.en_US
dc.identifier.citedreferenceLocarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679 – 693.en_US
dc.identifier.citedreferenceZoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res 2006; 71: 206 – 215.en_US
dc.identifier.citedreferenceSchildgen O, Sirma H, Funk A et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354: 1807 – 1812.en_US
dc.identifier.citedreferenceZoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 2006; 26: 171 – 180.en_US
dc.identifier.citedreferenceAllen MI, Deslauriers M, Andrews CW et al. Lamivudine Clinical Investigation Group. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670 – 1677.en_US
dc.identifier.citedreferenceAngus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292 – 297.en_US
dc.identifier.citedreferenceDurantel D, Carrouee-Durantel S, Werle-Lapostolle B et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004; 40: 855 – 864.en_US
dc.identifier.citedreferenceTenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 3498 – 3507.en_US
dc.identifier.citedreferenceVilleneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085 – 1089.en_US
dc.identifier.citedreferenceYang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625 – 633.en_US
dc.identifier.citedreferenceDelaney WE 4th, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833 – 11841.en_US
dc.identifier.citedreferenceVillet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253 – 1261.en_US
dc.identifier.citedreferenceBrunelle MN, Jacquard AC, Pichoud C et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391 – 1398.en_US
dc.identifier.citedreferenceDandri M, Lutgehetmann M, Volz T, Petersen J. Small animal model systems for studying hepatitis B virus replication and pathogenesis. Semin Liver Dis 2006; 26: 181 – 191.en_US
dc.identifier.citedreferenceStuyver L, van Geyt C, De Gendt S et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 702 – 707.en_US
dc.identifier.citedreferenceLok AS, Zoulim F, Locarnini S et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729 – 3734.en_US
dc.identifier.citedreferenceNafa S, Ahmed S, Tavan D et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078 – 1088.en_US
dc.identifier.citedreferenceZoulim F. New nucleic acid diagnostic tests in viral hepatitis. Semin Liver Dis 2006; 26: 309 – 317.en_US
dc.identifier.citedreferenceYuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785 – 791.en_US
dc.identifier.citedreferenceZoulim F, Poynard T, Degos F et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006; 13: 278 – 288.en_US
dc.identifier.citedreferenceLok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714 – 1722.en_US
dc.identifier.citedreferenceLiaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521 – 1531.en_US
dc.identifier.citedreferenceHadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847 – 851.en_US
dc.identifier.citedreferenceDienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105 – 117.en_US
dc.identifier.citedreferenceHadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743 – 1751.en_US
dc.identifier.citedreferenceSherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039 – 2049.en_US
dc.identifier.citedreferenceLee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385 – 1391.en_US
dc.identifier.citedreferenceSchreibman IR, Schiff ER. Prevention and treatment of recurrent hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006; 5: 8.en_US
dc.identifier.citedreferenceVillet S, Ollivet A, Pichoud C et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46: 531 – 538.en_US
dc.identifier.citedreferenceYim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703 – 712.en_US
dc.identifier.citedreferenceThibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. Aids 2002; 16: 131 – 133.en_US
dc.identifier.citedreferenceLampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414 – 1419.en_US
dc.identifier.citedreferenceLampertico P, Marzano A, Levrero M et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 2006; 44: Abstract LB5, p693A.en_US
dc.identifier.citedreferenceFung SK, Andreone P, Han SH et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937 – 943.en_US
dc.identifier.citedreferenceDi Bisceglie AM, Lai CL, Gane E et al. Telbivudine globe trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44: Abstract 112, p230A.en_US
dc.identifier.citedreferenceLai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528 – 536.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2893.2007.00915.x.pdf
Size:
266.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.